1. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUVmax ratio-based evaluation system
- Author
-
Yu-Mo Zhao, Si Tang, Wei Fan, Zizheng Xiao, Ying-Ying Hu, Yong-Luo Jiang, Mei-Ting Chen, Xu Zhang, and Ying-He Li
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Receiver operating characteristic ,business.industry ,Proportional hazards model ,General Medicine ,medicine.disease ,Gastroenterology ,Lesion ,Internal medicine ,medicine ,Cutoff ,Radiology, Nuclear Medicine and imaging ,Rituximab ,medicine.symptom ,business ,Diffuse large B-cell lymphoma ,Survival analysis ,medicine.drug - Abstract
The aim of this study was to determine a better criterion for end-of-treatment PET (EoT-PET) assessment and prognostic evaluation of patients with diffuse large B cell lymphoma (DLBCL). EoT-PET scans were assessed using the visual Deauville 5-point scale (5PS) and LLR, the maximum standard uptake value ratio between the lesion and the liver. The cutoff value of LLR was obtained by receiver operator characteristic curve analysis. Patient outcomes were compared using Kaplan–Meier survival analysis. Prognostic indexes of different criteria were compared. Multivariate Cox regression analysis was performed to evaluate the prognostic factors. Four hundred forty-nine newly diagnosed DLBCL patients who received rituximab-based immunochemotherapy were included, and the median follow-up duration was 41.4 months. Patients with Deauville score (DS) 4 displayed significantly longer PFS and OS compared with patients with DS 5 (both p
- Published
- 2021
- Full Text
- View/download PDF